ARCHIVES

Gleevec Maintenance Therapy Showed Significant Benefits At Three Years in Phase III Trial

This article is from The Cancer Letter archive.

Vol. 35 No. 4 | April 27, 2012

Download PDF Visit The Full Archive

Related Articles

FDA Advisors OK Levamisole, Conditional New Tamoxifen Use

February 9, 1990

Youth Smoking Linked To Exposure In Movies

December 30, 2005

NCI Denies GAO Report That Backlog Still Exists, Says Most were Published As Research Results

May 18, 1979

ASCO and CAP Issue Guideline To Improve HER2 Testing

October 25, 2013

FDA cancer therapeutics review split among three units in reorganization.

October 10, 2003

DCT Board Approves Three New BRMP RFAs For Immunologic Research, $1.5 Million A Year

February 27, 1987